

Workshop on Pharmacogenomics: from science to clinical care

Session 4 : Pharmacogenomics guided treatments in clinical care: experience from patients and healthcare professionals

London, October 8-9, 2012

David H.-U. Haerry, EATG



Pharmacogenomics in HIV/HCV

A lot of experience accumulated

- ✓ **Hypersensitivity testing pre-abacavir use**
(HLA B*5701 genetic test)
- ✓ **IL28B polymorphism (HCV)**
- ✓ **Studies show genetic factors influence plasma concentrations in NNRTI**
(983T>C genotypes)
- ✓ **Tropism testing pre-maraviroc use**



Areas of urgent improvement

- ✓ Pharmacogenetic testing to be an option in pIII pivotal trials for cases of hepatotoxicity, hypersensitivity, rash – address IC, data protection
- ✓ Interpretation pharmacogenetic testing
- ✓ Regulatory differences FDA/AUS/EMA when better assays become available – case of Maraviroc